The Factors That May Predict Response to Rituximab Therapy in Recurrent Focal Segmental Glomerulosclerosis : A Systematic Review

Abstract EN

Recurrence of FSGS occurs in 30–40% of allografts.

Therapies for recurrence are not well established.

We retrieved all published reports depicting kidney transplant recipients with focal segmental glomerulosclerosis (FSGS) recurrence, treated with rituximab, to determine factors associated with treatment response.

We found 18 reports of 39 transplant recipients who received rituximab.

By univariate analysis for two outcomes (no response versus any response), fewer rituximab infusions and normal serum albumin at recurrence were associated with treatment response.

For 3 outcomes (no response, partial and complete remission), male gender, fewer rituximab infusions, shorter time to rituximab treatment, and normal serum albumin were associated with remission.

Multivariate analysis for both models revealed that normal serum albumin at FSGS recurrence and lower age at transplant were associated with response.

Rituximab for recurrence of FSGS may be beneficial for only some patients.

A younger age at transplant and normal serum albumin level at recurrence diagnosis may predict response.